HABITROL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HABITROL (HABITROL).
Nicotine acts as an agonist at nicotinic acetylcholine receptors, stimulating dopamine release in the nucleus accumbens, which mediates reward and craving reduction.
| Metabolism | Primarily hepatic via CYP2A6 and CYP2B6; also metabolized by aldehyde oxidase and N-glucuronidation. |
| Excretion | Primarily renal (10-20% unchanged; 60-70% as metabolites cotinine and nicotine-N'-oxide); 5-10% biliary/fecal. |
| Half-life | 2 hours (nicotine); 16 hours (cotinine metabolite) — accumulation with chronic use. |
| Protein binding | 5-20% (albumin). |
| Volume of Distribution | 2-3 L/kg; indicates extensive tissue distribution (lungs, liver, brain). |
| Bioavailability | Transdermal: 80-90% (continuous absorption); Oral: 45% (first-pass metabolism). |
| Onset of Action | Transdermal: 2-4 hours to steady state; maximal effect at 8-12 hours. |
| Duration of Action | 24 hours per patch; sustained release due to depot in skin. |
Transdermal: Apply one patch daily. Initial dose based on smoking history: >10 cigarettes/day: 21 mg/day patch; ≤10 cigarettes/day: 14 mg/day patch. Titrate to 7 mg/day patch as tolerated.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for renal impairment. Data not available for severe renal failure. |
| Liver impairment | No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to reduced clearance. |
| Pediatric use | Not approved for use in patients younger than 18 years. Safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; monitor for adverse effects due to potential decreased renal function and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HABITROL (HABITROL).
| Breastfeeding | Nicotine is excreted into breast milk. Milk-to-plasma ratio (M/P) is approximately 2.9. Concentrations in milk are higher than maternal plasma. Infant exposure may cause adverse effects such as tachycardia, restlessness, and feeding difficulties. Breastfeeding is generally avoided during nicotine replacement therapy due to risks. If used, monitor infant for nicotine toxicity. |
| Teratogenic Risk | Nicotine (HABITROL) is associated with fetal risks in all trimesters. First trimester: increased risk of spontaneous abortion, preterm birth, and low birth weight. Second and third trimesters: continued risk of reduced fetal growth, placental abruption, and preterm delivery. Nicotine is a known teratogen; however, smoking cessation benefits may outweigh risks. Data limited for nicotine replacement therapy specifically. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to nicotine or any component of the formulation; immediately post-myocardial infarction; life-threatening arrhythmias; severe or worsening angina; active temporomandibular joint disease (for gum formulation)."]
| Precautions | ["Risk of nicotine toxicity if used with other nicotine products; may worsen hypertension; caution in cardiovascular disease, diabetes, and hyperthyroidism; potential for skin irritation with transdermal patch."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and smoking cessation progress. Fetal monitoring includes serial ultrasound for growth, fetal heart rate monitoring, and assessment of placental function. Maternal monitoring for signs of nicotine toxicity (nausea, dizziness, tachycardia). For pregnant women, consider non-pharmacologic interventions first. |
| Fertility Effects | Nicotine may impair fertility in both sexes. In females: decreased ovarian reserve, altered menstrual cycle, increased risk of infertility. In males: reduced sperm count, motility, and morphology. Smoking cessation improves fertility outcomes. Data specific to HABITROL are lacking, but nicotine itself has documented negative effects on fertility. |